Berberine for NAFLD: What 17 RCTs Show on Liver Enzymes and Steatosis

Berberine has been studied extensively for glycemic control, where its glucose-lowering effects rival metformin in modest trials. Its application to non-alcoholic fatty liver disease (now formally renamed metabolic dysfunction-associated steatotic liver disease, or MASLD) is a quieter story but a substantive one. A 2025 systematic review pulled together 17 randomized trials (n=1,408) using berberine in patients with biopsy-confirmed or imaging-confirmed NAFLD/MASLD, and the pooled effects on liver enzymes and steatosis are larger than what most readers familiar with berberine for diabetes might expect.

What the pooled data show

Pooled across the 17 trials, berberine at 0.9–1.5 g/day for 12–24 weeks lowered ALT by a mean of 12 U/L (95% CI 8–16) and AST by 9 U/L. Hepatic steatosis grade by ultrasound or controlled attenuation parameter (CAP, from FibroScan) improved by roughly one grade in 38% of berberine-treated patients versus 14% of controls. Effects on fibrosis markers were smaller and inconsistent — the trials were not long enough or large enough to detect histological fibrosis change.

Glycemic and lipid endpoints moved in the expected direction: fasting glucose down ~10 mg/dL, HOMA-IR down ~0.8, total cholesterol down ~17 mg/dL, triglycerides down ~30 mg/dL. The metabolic profile improvements are likely the upstream mechanism of the liver findings rather than a direct hepatic effect.

How berberine compares to lifestyle and pharmacotherapy

The trial-level comparison most patients want is: how does this stack up against the things my hepatologist already recommends? Three trials in the review compared berberine head-to-head with metformin: ALT reduction was comparable, and berberine had fewer GI complaints at the doses used. Two trials added berberine to ongoing lifestyle intervention and saw additive benefit. None compared berberine to the FDA-approved MASH agent resmetirom (Rezdiffra), which entered the market in 2024 — that head-to-head trial does not exist, and is unlikely to be commercially sponsored.

The clinical reality in 2026 is that resmetirom is the only labeled pharmacotherapy for biopsy-confirmed MASH with fibrosis, and it is expensive. Berberine is an option in the larger MASLD population that does not yet meet the resmetirom label, or for patients who cannot access the prescription drug. It is not a substitute for weight loss, which remains the single most effective intervention with histological data behind it.

Bioavailability and form notes

Berberine has very low oral bioavailability (less than 1% as parent compound), which is why the standard dose is 500 mg three times daily — total daily dose around 1,500 mg. Splitting the dose matters because plasma half-life of free berberine is short. Dihydroberberine, a marketed reduced form, claims better absorption but has thin head-to-head human data; the 2024 dose-finding work suggested it does raise circulating berberine derivatives but did not show clearly superior clinical endpoints.

Two practical safety items: berberine inhibits CYP3A4 and CYP2D6, raising plasma levels of many medications including statins, cyclosporine, and some antiarrhythmics; check interactions. And in pregnancy and neonates, berberine displaces bilirubin from albumin and is associated with kernicterus risk — it is contraindicated in pregnancy and in nursing mothers of newborns.

Bottom line

Across 17 RCTs, berberine 1.0–1.5 g/day for at least 12 weeks meaningfully lowers ALT, AST, and imaging-measured liver fat in MASLD patients, with effects on glycemic and lipid markers in parallel. It does not substitute for weight loss or for prescription pharmacotherapy in biopsy-confirmed MASH with fibrosis, but it is a reasonable adjunct in the larger pre-MASH population. Watch for drug interactions and avoid in pregnancy.